Innovating Works

MABIOS

Financiado
The first microalgae platform for the production of anticancer biopharmaceutical...
Manufacturing costs remain one of the major obstacles to providing effective treatment of cancer patients. Anticancer agents are often complex biopharmaceuticals that are expensive to manufacture, requiring use of living cell line... Manufacturing costs remain one of the major obstacles to providing effective treatment of cancer patients. Anticancer agents are often complex biopharmaceuticals that are expensive to manufacture, requiring use of living cell lines with difficult-to-control production processes, limited yields and time-consuming purification steps. There is an urgent unmet need for an improved manufacturing process of biopharmaceuticals, to meet the high demand and lower the price of oncologic treatments. We will revolutionize the way biopharmaceuticals are produced by developing a microalgae based biorefinery platform. These biorefineries will utilize genetically engineered microalgae to efficiently produce pharmaceutical agents. Microalgae are photosynthetic micro-organisms that have unique advantages as biopharmaceutical production systems, including high growth rate, ease of cultivation and low growth costs, enabling cost effective and scalable yield of active ingredients. These will be recombinant proteins, small molecules or therapeutic peptides, starting with Paclitaxel as showcase, one of the world’s best sold anticancer drugs used as the first line treatment of a several solid tumours. Our platform has the potential to become the new manufacturing method of choice for production of highly needed biopharmaceuticals. Microalgae Works is an ambitious Dutch start-up with the mission to make anticancer treatment affordable for every patient through a drastic reduction of manufacturing costs. We are supported by leading companies in the field of biomanufacturing. The MABIOS project will (1) create a clear overview of the market opportunity for micro-algae based production of paclitaxel, (2) develop a de-risked plan for the technical development of our platform, (3) evaluate the necessary regulatory roadmap to enter the market, and (4) formulate an investor-proof business plan. We aim to become the frontrunner in biopharmaceutical production utilizing microalgae. ver más
31/01/2020
MAW
71K€
Duración del proyecto: 6 meses Fecha Inicio: 2019-07-05
Fecha Fin: 2020-01-31

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2020-01-31
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
Presupuesto El presupuesto total del proyecto asciende a 71K€
Líder del proyecto
MICROALGAE WORKS BV No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5